Open access · CC-BY via OpenAlex

Osteoporosis Therapy: Bone Modeling during Growth and Aging

Frontiers in Endocrinology · 2017 · ▲ 27 citations

Loss of proteostasis Human

Abstract

TABLE 1 | Expected effects of anabolic osteoporosis agents on bone modeling.Anabolic osteoporosis agents Bone modeling Clinical status parathyroid hormone Teriparatide Daily (20 μg/day) a + Approval Weekly (56.5 μg/week) a + Approval b parathyroid hormone-related protein Abaloparatide (daily, 80 μg/day) a ++ Phase 3 Anti-sclerostin antibody Romosozumab (monthly, 210 mg/month) a +++ Phase 3 a Subcutaneous injection.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: OpenAlex
DOI: 10.3389/fendo.2017.00046
Canonical: link ↗
Fetched: 2026-10-18 MST

Cite this

APA

Sugiyama, T., & Oda, H. (2017). Osteoporosis Therapy: Bone Modeling during Growth and Aging. <em>Frontiers in Endocrinology</em>. https://doi.org/10.3389/fendo.2017.00046

Vancouver

Sugiyama T, Oda H. Osteoporosis Therapy: Bone Modeling during Growth and Aging. Frontiers in Endocrinology. 2017. doi:10.3389/fendo.2017.00046.

BibTeX

@article{toshihiro2017Osteop, title = {Osteoporosis Therapy: Bone Modeling during Growth and Aging}, author = {Toshihiro Sugiyama and Hiromi Oda}, journal = {Frontiers in Endocrinology}, year = {2017}, doi = {10.3389/fendo.2017.00046}, }